Patrick Soon-Shiong

Born in South Africa on July 29, 1952, Patrick Soon-Shiong’s early career was rooted in the demanding field of transplant surgery. His transition from hands-on patient care to pioneering pharmaceutical development was driven by a profound understanding of unmet medical needs. This led to the invention of Abraxane, a nanoparticle albumin-bound paclitaxel, which revolutionized treatment for several aggressive cancers, including lung, breast, and pancreatic cancers.

Abraxane's efficacy lies in its innovative delivery system, which enhances drug distribution and reduces side effects, marking a significant advancement in chemotherapy. His ongoing work in developing novel therapeutic agents, such as Anktiva, a new class of immunotherapy drug for non-muscle invasive bladder cancer approved in 2024, underscores his commitment to pushing the boundaries of medical science and offering new hope to patients facing life-threatening diseases.

Beyond his direct contributions to drug development, Dr. Soon-Shiong is the visionary founder of NantWorks, a dynamic conglomerate of healthcare, biotechnology, and artificial intelligence startups. This ambitious network aims to integrate cutting-edge technologies to create a more connected and effective healthcare ecosystem.

NantWorks is at the forefront of leveraging big data, AI, and advanced diagnostics to personalize medicine and accelerate the discovery of new treatments. His academic affiliations, including adjunct professorships at UCLA and visiting professorships at prestigious institutions like Imperial College London and Dartmouth College, highlight his dedication to fostering research and education. As Executive Chairman and Global Chief Medical & Technology Officer at ImmunityBio, he continues to lead efforts in developing next-generation therapeutics and diagnostics.

Patrick Soon-Shiong's influence extends far beyond the medical and technological spheres. His significant financial success, stemming from his innovative ventures, has positioned him as one of the wealthiest individuals globally, often recognized as the richest doctor in the world. This wealth has enabled him to diversify his investments and engage in significant philanthropic endeavors through the Chan Soon-Shiong Family Foundation, which supports various charitable causes.

Furthermore, his ownership stake in the iconic Los Angeles Lakers basketball team demonstrates his passion for sports and his engagement with the entertainment industry. In 2018, he acquired the Los Angeles Times, a pivotal move that places him at the helm of a major media organization, influencing public discourse and information dissemination.

The sheer volume of Dr. Soon-Shiong's intellectual property is staggering, with over 850 worldwide patents to his name. Each patent represents a unique invention or discovery, a testament to his relentless innovation and problem-solving capabilities.

These patents cover a wide range of technologies and medical applications, forming the bedrock of his business empire and contributing significantly to advancements in healthcare. His work has not only generated substantial economic value but has also had a profound global impact, improving patient outcomes and shaping the future of medicine. His journey from a medical practitioner to a global business leader and innovator serves as an inspiring example of how scientific curiosity, entrepreneurial spirit, and a commitment to improving human health can lead to extraordinary achievements.